Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06318234Recruiting

PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer

Role: lead

NCT06234319Recruiting

CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma

Role: lead

NCT06287411Recruiting

Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies

Role: lead

NCT06183554Unknown

CXCR4 Targeted PET Imaging in the Diagnosis and Identification of Primary Aldosteronism

Role: lead

NCT05824962Unknown

A Non-invasive Diagnostic Model for Intestinal Fibrosis in Crohn's Disease Based on 18F-FAPI PET Imaging

Role: lead

All 5 trials loaded